Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

~24 mi. (Cremona, Italy, +153 more cities)

UO Oncologia, ASST di Cremona - Istituti Ospitalieri - Ospedale di Cremona

Bladder Urothelial Carcinoma, +2 more conditions

BCG solution, +1 more drug

immunotherapy

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

~24 mi. (Cremona, Italy, +154 more cities)

ASST di Cremona - Azienda Socio Sanitaria Territoriale di Cremona

ALK Alternative Transcription Site, +7 more biomarkers

Non-Small Cell Lung Carcinoma

alectinib, +2 more drugs

immunotherapy, +1 more type

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

~24 mi. (Guastalla, Italy, +64 more cities)

Ospedale Civile di Guastalla

ER Positive, +1 more biomarker

Breast Carcinoma

anastrozole, +2 more drugs

hormone therapy

Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

~24 mi. (Cremona, Italy, +120 more cities)

Ospedale di Cremona

FGFR3 A391E, +9 more biomarkers

Urothelial Carcinoma

infigratinib

targeted therapy

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

~26 mi. (Parma, Italy, +383 more cities)

Azienda Ospedaliero Universitaria di Parma

ER Negative, +2 more biomarkers

Breast Carcinoma

atezolizumab, +4 more drugs

chemotherapy, +1 more type

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

~26 mi. (Parma, Italy, +122 more cities)

A.O.U. di Parma

Prostate Adenocarcinoma

radium Ra 223 dichloride

radiation therapy

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

~26 mi. (Parma, Italy, +206 more cities)

Azienda Ospedaliero Universitaria di Parma

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Non-Small Cell Lung Carcinoma

atezolizumab, +1 more drug

immunotherapy

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

~26 mi. (Parma, Italy, +151 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

niraparib, +1 more drug

immunotherapy, +1 more type

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

~26 mi. (Parma, Italy, +103 more cities)

Azienda Ospedaliero Universitaria di Parma

EGFR Exon 19 Deletion, +1 more biomarker

Non-Small Cell Lung Carcinoma

patritumab deruxtecan

chemotherapy, +1 more type

Study of Lorlatinib In Participants With Anaplastic Lymphoma Kinase (ALK) -Positive NSCLC

~26 mi. (Parma, Italy, +25 more cities)

Azienda Ospedaliero Universitaria di Parma

ALK Fusion

Non-Small Cell Lung Carcinoma

lorlatinib

targeted therapy

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

~26 mi. (Parma, Italy, +57 more cities)

GSK Investigational Site

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

cobolimab, +7 more drugs

chemotherapy, +2 more types

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

~39 mi. (Reggio nell'Emilia, Italy, +115 more cities)

Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS

ERBB2 Amplification, +7 more biomarkers

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type